TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Achieve Life Sciences ( (ACHV) ) has provided an update.
On September 11, 2025, Achieve Life Sciences announced that Dr. Cindy Jacobs would resign from her roles as Chief Medical Officer and President, effective October 6, 2025. Following her resignation, Dr. Jacobs will continue as a consultant until the FDA approves the company’s New Drug Application for cytisinicline. She will receive a severance package, including a cash payment, accelerated vesting of stock options, and legal fee reimbursements.
The most recent analyst rating on (ACHV) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Achieve Life Sciences stock, see the ACHV Stock Forecast page.
Spark’s Take on ACHV Stock
According to Spark, TipRanks’ AI Analyst, ACHV is a Underperform.
Achieve Life Sciences is navigating typical early-stage biotech challenges, including zero revenue and significant financial losses. While there are promising developments such as the upcoming NDA submission and strong clinical trial progress, these are offset by high operating expenses and dependency on future financing and regulatory approvals. Technical indicators reflect a downward trend, and the valuation remains unattractive with a negative P/E ratio.
To see Spark’s full report on ACHV stock, click here.
More about Achieve Life Sciences
Achieve Life Sciences, Inc. operates in the pharmaceutical industry, focusing on developing and commercializing cytisinicline, a product aimed at aiding smoking cessation.
Average Trading Volume: 1,122,399
Technical Sentiment Signal: Sell
Current Market Cap: $161.5M
For detailed information about ACHV stock, go to TipRanks’ Stock Analysis page.